Actieve functies van Samantha Vieira
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Operationeel Directeur | 12-07-2022 | - |
Loopbaan van Samantha Vieira
Eerdere bekende functies van Samantha Vieira
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
BIOGEN INC. | Corporate Officer/Principal | 01-06-2019 | 01-08-2021 |
Statistieken
Internationaal
Verenigde Staten | 2 |
Zwitserland | 2 |
Operationeel
Chief Operating Officer | 1 |
Corporate Officer/Principal | 1 |
Sectoraal
Health Technology | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
BIOGEN INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Health Technology |
- Beurs
- Insiders
- Samantha Vieira
- Ervaring